U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Sensitive Lung Small Cell Carcinoma

MedGen UID:
1683050
•Concept ID:
C4764256
•
Neoplastic Process
Synonym: Platinum-Sensitive Small Cell Lung Carcinoma

Definition

Lung small cell carcinoma that is sensitive to platinum therapy. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPlatinum-Sensitive Lung Small Cell Carcinoma

Professional guidelines

PubMed

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R, Rengarajan B, Naveh N, Boccuti A, Park JE, Adeyemi A, Caisip C, Jansen JP, Wilson FR
J Comp Eff Res 2023 May;12(5):e220098. Epub 2023 Apr 20 doi: 10.57264/cer-2022-0098. PMID: 37079341Free PMC Article
Lurbinectedin for the treatment of small cell lung cancer.
Li L, Zou C, Dong S, Wu ZX, Ashby CR Jr, Chen ZS, Qiu C
Drugs Today (Barc) 2021 Jun;57(6):377-385. doi: 10.1358/dot.2021.57.6.3294559. PMID: 34151904
Optimal drugs for second-line treatment of patients with small-cell lung cancer.
Rossi A, Sacco PC, Sgambato A, Casaluce F, Santabarbara G, Palazzolo G, Maione P, Gridelli C
Expert Opin Pharmacother 2016;17(7):969-76. Epub 2016 Feb 29 doi: 10.1517/14656566.2016.1154539. PMID: 26878692

Recent clinical studies

Etiology

Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
Zhao L, Zhao Z, Yan X, Hu X, Feng J, Yu S
Technol Cancer Res Treat 2024 Jan-Dec;23:15330338241227055. doi: 10.1177/15330338241227055. PMID: 38258375Free PMC Article
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
Takahashi N, Hao Z, Villaruz LC, Zhang J, Ruiz J, Petty WJ, Mamdani H, Riess JW, Nieva J, Pachecho JM, Fuld AD, Shum E, Chauhan A, Nichols S, Shimellis H, McGlone J, Sciuto L, Pinkiert D, Graham C, Shelat M, Kattappuram R, Abel M, Schroeder B, Upadhyay D, Krishnamurthy M, Sharma AK, Kumar R, Malin J, Schultz CW, Goyal S, Redon CE, Pommier Y, Aladjem MI, Gore SD, Steinberg SM, Vilimas R, Desai P, Thomas A
JAMA Oncol 2023 Dec 1;9(12):1669-1677. doi: 10.1001/jamaoncol.2023.4025. PMID: 37824137Free PMC Article
Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes.
Moser SS, Bar J, Kan I, Ofek K, Cohen R, Khandelwal N, Shalev V, Chodick G, Siegelmann-Danieli N
Curr Oncol 2021 Jan 8;28(1):317-331. doi: 10.3390/curroncol28010036. PMID: 33435584Free PMC Article
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G, Tiseo M, Kenmotsu H, Kazushige W, Di Battista M, Cavallo G, Carloni F, Bongiovanni A, Burgio MA, Casanova C, Metro G, Scarpi E, Korkmaz T, Selcuk S, Roopa K, Califano R
Clin Lung Cancer 2015 Nov;16(6):e223-8. Epub 2015 Apr 24 doi: 10.1016/j.cllc.2015.04.006. PMID: 25983005
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R
Lung Cancer 2011 Jun;72(3):378-83. Epub 2010 Oct 15 doi: 10.1016/j.lungcan.2010.09.009. PMID: 20950888

Diagnosis

Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
Postel-Vinay S, Coves J, Texier M, Aldea M, Gazzah A, Dómine M, Planchard D, De Las Peñas R, Sala Gonzalez MA, Viteri S, Perez J, Ortega AL, Moran T, Camps C, Lopez-Martin A, Provencio M, Soria JC, Besse B, Massuti B, Rosell R
Br J Cancer 2024 Feb;130(3):417-424. Epub 2023 Dec 14 doi: 10.1038/s41416-023-02514-5. PMID: 38097741Free PMC Article
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
Takahashi N, Hao Z, Villaruz LC, Zhang J, Ruiz J, Petty WJ, Mamdani H, Riess JW, Nieva J, Pachecho JM, Fuld AD, Shum E, Chauhan A, Nichols S, Shimellis H, McGlone J, Sciuto L, Pinkiert D, Graham C, Shelat M, Kattappuram R, Abel M, Schroeder B, Upadhyay D, Krishnamurthy M, Sharma AK, Kumar R, Malin J, Schultz CW, Goyal S, Redon CE, Pommier Y, Aladjem MI, Gore SD, Steinberg SM, Vilimas R, Desai P, Thomas A
JAMA Oncol 2023 Dec 1;9(12):1669-1677. doi: 10.1001/jamaoncol.2023.4025. PMID: 37824137Free PMC Article
Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R, Rengarajan B, Naveh N, Boccuti A, Park JE, Adeyemi A, Caisip C, Jansen JP, Wilson FR
J Comp Eff Res 2023 May;12(5):e220098. Epub 2023 Apr 20 doi: 10.57264/cer-2022-0098. PMID: 37079341Free PMC Article
Lurbinectedin for the treatment of small cell lung cancer.
Li L, Zou C, Dong S, Wu ZX, Ashby CR Jr, Chen ZS, Qiu C
Drugs Today (Barc) 2021 Jun;57(6):377-385. doi: 10.1358/dot.2021.57.6.3294559. PMID: 34151904
Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes.
Moser SS, Bar J, Kan I, Ofek K, Cohen R, Khandelwal N, Shalev V, Chodick G, Siegelmann-Danieli N
Curr Oncol 2021 Jan 8;28(1):317-331. doi: 10.3390/curroncol28010036. PMID: 33435584Free PMC Article

Therapy

Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
Zhao L, Zhao Z, Yan X, Hu X, Feng J, Yu S
Technol Cancer Res Treat 2024 Jan-Dec;23:15330338241227055. doi: 10.1177/15330338241227055. PMID: 38258375Free PMC Article
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
Postel-Vinay S, Coves J, Texier M, Aldea M, Gazzah A, Dómine M, Planchard D, De Las Peñas R, Sala Gonzalez MA, Viteri S, Perez J, Ortega AL, Moran T, Camps C, Lopez-Martin A, Provencio M, Soria JC, Besse B, Massuti B, Rosell R
Br J Cancer 2024 Feb;130(3):417-424. Epub 2023 Dec 14 doi: 10.1038/s41416-023-02514-5. PMID: 38097741Free PMC Article
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
Takahashi N, Hao Z, Villaruz LC, Zhang J, Ruiz J, Petty WJ, Mamdani H, Riess JW, Nieva J, Pachecho JM, Fuld AD, Shum E, Chauhan A, Nichols S, Shimellis H, McGlone J, Sciuto L, Pinkiert D, Graham C, Shelat M, Kattappuram R, Abel M, Schroeder B, Upadhyay D, Krishnamurthy M, Sharma AK, Kumar R, Malin J, Schultz CW, Goyal S, Redon CE, Pommier Y, Aladjem MI, Gore SD, Steinberg SM, Vilimas R, Desai P, Thomas A
JAMA Oncol 2023 Dec 1;9(12):1669-1677. doi: 10.1001/jamaoncol.2023.4025. PMID: 37824137Free PMC Article
Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R, Rengarajan B, Naveh N, Boccuti A, Park JE, Adeyemi A, Caisip C, Jansen JP, Wilson FR
J Comp Eff Res 2023 May;12(5):e220098. Epub 2023 Apr 20 doi: 10.57264/cer-2022-0098. PMID: 37079341Free PMC Article
Bevacizumab: a review of its use in advanced cancer.
Keating GM
Drugs 2014 Oct;74(16):1891-1925. doi: 10.1007/s40265-014-0302-9. PMID: 25315029

Prognosis

Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
Takahashi N, Hao Z, Villaruz LC, Zhang J, Ruiz J, Petty WJ, Mamdani H, Riess JW, Nieva J, Pachecho JM, Fuld AD, Shum E, Chauhan A, Nichols S, Shimellis H, McGlone J, Sciuto L, Pinkiert D, Graham C, Shelat M, Kattappuram R, Abel M, Schroeder B, Upadhyay D, Krishnamurthy M, Sharma AK, Kumar R, Malin J, Schultz CW, Goyal S, Redon CE, Pommier Y, Aladjem MI, Gore SD, Steinberg SM, Vilimas R, Desai P, Thomas A
JAMA Oncol 2023 Dec 1;9(12):1669-1677. doi: 10.1001/jamaoncol.2023.4025. PMID: 37824137Free PMC Article
Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes.
Moser SS, Bar J, Kan I, Ofek K, Cohen R, Khandelwal N, Shalev V, Chodick G, Siegelmann-Danieli N
Curr Oncol 2021 Jan 8;28(1):317-331. doi: 10.3390/curroncol28010036. PMID: 33435584Free PMC Article
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G, Tiseo M, Kenmotsu H, Kazushige W, Di Battista M, Cavallo G, Carloni F, Bongiovanni A, Burgio MA, Casanova C, Metro G, Scarpi E, Korkmaz T, Selcuk S, Roopa K, Califano R
Clin Lung Cancer 2015 Nov;16(6):e223-8. Epub 2015 Apr 24 doi: 10.1016/j.cllc.2015.04.006. PMID: 25983005
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R
Lung Cancer 2011 Jun;72(3):378-83. Epub 2010 Oct 15 doi: 10.1016/j.lungcan.2010.09.009. PMID: 20950888
Clinical perspectives on platinum resistance.
Giaccone G
Drugs 2000;59 Suppl 4:9-17; discussion 37-8. doi: 10.2165/00003495-200059004-00002. PMID: 10864226

Clinical prediction guides

Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
Zhao L, Zhao Z, Yan X, Hu X, Feng J, Yu S
Technol Cancer Res Treat 2024 Jan-Dec;23:15330338241227055. doi: 10.1177/15330338241227055. PMID: 38258375Free PMC Article
Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes.
Moser SS, Bar J, Kan I, Ofek K, Cohen R, Khandelwal N, Shalev V, Chodick G, Siegelmann-Danieli N
Curr Oncol 2021 Jan 8;28(1):317-331. doi: 10.3390/curroncol28010036. PMID: 33435584Free PMC Article
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
Gregorc V, Cavina R, Novello S, Grossi F, Lazzari C, Capelletto E, Genova C, Salini G, Lambiase A, Santoro A
Oncologist 2018 Oct;23(10):1133-e112. Epub 2018 Aug 3 doi: 10.1634/theoncologist.2018-0292. PMID: 30076277Free PMC Article
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA
Cancer Res 2017 Jul 15;77(14):3870-3884. Epub 2017 May 10 doi: 10.1158/0008-5472.CAN-16-3409. PMID: 28490518Free PMC Article
Clinical perspectives on platinum resistance.
Giaccone G
Drugs 2000;59 Suppl 4:9-17; discussion 37-8. doi: 10.2165/00003495-200059004-00002. PMID: 10864226

Recent systematic reviews

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R, Rengarajan B, Naveh N, Boccuti A, Park JE, Adeyemi A, Caisip C, Jansen JP, Wilson FR
J Comp Eff Res 2023 May;12(5):e220098. Epub 2023 Apr 20 doi: 10.57264/cer-2022-0098. PMID: 37079341Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...